Moderna experienced notable upward momentum driven primarily by a key structural catalyst as the company formally joined the Nasdaq-100 Index prior to the market open. The index inclusion created mandatory buying pressure from passive funds and institutional portfolio managers benchmarked to the index, resulting in significant intraday trading volume and heightened price volatility as technical rebalancing demand flooded the tape.

Beyond index-related capital flows, the broader narrative surrounding Moderna continues to be energized by its clinical transition from a pandemic-focused vaccine producer to a diversified oncology and mRNA therapeutics platform. Market sentiment…